psoriasis

Graphic image of an arrow nailing the bullseye of a target
Biotech

Oruka’s psoriasis data hailed as ‘outright win over Skyrizi’

Jefferies analysts predicted the asset could beat out AbbVie’s Skyrizi and generate sales of up to $10 billion.
Nick Paul Taylor Apr 27, 2026 9:51am
one white and yellow capsule farther ahead than four other same-colored blue capsules

Takeda clears path to FDA with phase 3 data on $4B psoriasis bet

Mar 28, 2026 3:00pm
A ballpoint pen rests on top of a stack of documents ready for signing

China biotech inks $135M deal for remaining rights to vTv med

Feb 2, 2026 10:10am
Graphic image of an arrow nailing the bullseye of a target

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Jan 6, 2026 9:05am
Takeda

Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib

Dec 18, 2025 7:55am
crown royalty king queen win

J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial

Sep 17, 2025 9:45am